vTv Therapeutics Inc.

VTVT

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001641489

None

No letter

4 of 13 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $89.9M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	thin data, degenerate inputs not computable: dilution, distress
Inputs computable	4 of 13
Graded from	filings received through Mar 10, 2026 255 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$16.08 2026-11-19; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 10, 2026

We are a late-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and inflammatory diseases with the goal of improving patient outcomes. Our lead product candidate, cadisegliatin (TTP399), is a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated in a Phase 3 clinical trial as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D).

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 73.2						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.6%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(2.7%)	(6.7%)	73.2	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 32.0					
Altman Z double-prime	(5.57)	0.31	54.7	705	2025-12-31
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(3.61x)			
interest expense must exceed $100,000					
Current ratio	13.54x	2.68x	9.4	781	2025-12-31
Growth and financing, sleeve percentile 10.4					
Revenue growth, three-year compound	not computable	9.6%			
current value must be positive and the base must exceed $100,000					
Free cash flow growth, three-year compound	not computable	11.1%			
four consecutive annual FCF observations are required; found 8					
Reinvestment rate	not computable	33.9%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	39.3%	3.2%	10.4	663	2025-12-31
Net share issuance, one year	not computable	1.6%			
two annual share counts are required; found 0					

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	4 of 13 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-11-19 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	41.8%	(1.7%)	76
Distance from 52-week high	(61.7%)	(31.7%)	23
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	not computable	0.6%	
Book value to price	not computable	0.29	
Sales to price	not computable	0.37	
Composite equity issuance, five years	not computable	13.5%	
Relative strength against the sector, log excess return	0.18	(0.19)	76
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$77.2M
Operating cash flow, four quarters	-$21.7M
Months of runway	42.6
Days since last periodic filing	15 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$610,291

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	-$20.9M	2019-12-31	2022-03-29	10-K	22-012258
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$21.8M	2019-12-31	2022-03-29	10-K	22-012258
3	income tax	us-gaap:IncomeTaxExpenseBenefit	$100,000	2019-12-31	2022-03-29	10-K	22-012258
4	total debt	us-gaap:LongTermDebt	$5.0M	2019-12-31	2020-02-21	10-K	20-005627
5	book equity	us-gaap:StockholdersEquity	-$49.0M	2019-12-31	2023-03-06	10-K	23-000008
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.8M	2019-12-31	2021-02-24	10-K	21-008149
7	total debt	us-gaap:LongTermDebt	$15.1M	2018-12-31	2019-02-26	10-K	19-004516
8	book equity	us-gaap:StockholdersEquity	-$82.9M	2018-12-31	2022-03-29	10-K	22-012258
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.7M	2018-12-31	2020-02-21	10-K	20-005627
10	net income	us-gaap:NetIncomeLoss	-$27.0M	2025-12-31	2026-03-10	10-K	26-000010
11	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$25.3M	2025-12-31	2026-03-10	10-K	26-000010
12	assets	us-gaap:Assets	$89.9M	2025-12-31	2026-03-10	10-K	26-000010
13	assets	us-gaap:Assets	$38.3M	2024-12-31	2026-03-10	10-K	26-000010
14	current assets	us-gaap:AssetsCurrent	$89.9M	2025-12-31	2026-03-10	10-K	26-000010
15	current liabilities	us-gaap:LiabilitiesCurrent	$6.6M	2025-12-31	2026-03-10	10-K	26-000010
16	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$326.7M	2025-12-31	2026-03-10	10-K	26-000010
17	operating income	us-gaap:OperatingIncomeLoss	-$32.8M	2025-12-31	2026-03-10	10-K	26-000010
18	book equity	us-gaap:StockholdersEquity	$64.4M	2025-12-31	2026-03-10	10-K	26-000010
19	liabilities	us-gaap:Liabilities	$25.5M	2025-12-31	2026-03-10	10-K	26-000010
20	depreciation amortization	us-gaap:Depreciation	$39,000	2019-12-31	2022-03-29	10-K	22-012258
21	operating income	us-gaap:OperatingIncomeLoss	-$25.5M	2023-12-31	2026-03-10	10-K	26-000010
22	interest expense	us-gaap:InterestExpense	$13,000	2023-12-31	2024-03-13	10-K	24-000012
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$0	2025-12-31	2026-03-10	10-K	26-000010
24	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.0M	2024-12-31	2026-03-10	10-K	26-000010
25	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$0	2023-12-31	2026-03-10	10-K	26-000010
26	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.0M	2022-12-31	2025-03-20	10-K	25-000014
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$0	2024-12-31	2025-03-20	10-K	25-000014
28	depreciation amortization	us-gaap:Depreciation	$89,000	2024-12-31	2026-03-10	10-K	26-000010
29	operating income	us-gaap:OperatingIncomeLoss	-$24.2M	2024-12-31	2026-03-10	10-K	26-000010
30	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$22.6M	2024-12-31	2026-03-10	10-K	26-000010
31	income tax	us-gaap:IncomeTaxExpenseBenefit	$100,000	2024-12-31	2026-03-10	10-K	26-000010
32	current assets	us-gaap:AssetsCurrent	$38.1M	2024-12-31	2026-03-10	10-K	26-000010
33	current liabilities	us-gaap:LiabilitiesCurrent	$5.2M	2024-12-31	2026-03-10	10-K	26-000010
34	current assets	us-gaap:AssetsCurrent	$10.7M	2023-12-31	2025-03-20	10-K	25-000014
35	current liabilities	us-gaap:LiabilitiesCurrent	$10.6M	2023-12-31	2025-03-20	10-K	25-000014
36	assets	us-gaap:Assets	$11.0M	2023-12-31	2025-03-20	10-K	25-000014
37	assets	us-gaap:Assets	$33.2M	2022-12-31	2024-03-13	10-K	24-000012

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.